GlaxoSmithKline has warned of impending shortages of two of its vaccines.
Owing to a delay in the start-up of a new manufacturing plant, capacity normally reserved for producing typhoid antigen for Typherix and Hepatyrix has been switched to the production of critical childhood vaccines. This situation is expected to last until the end of 2013. Current stocks of Typherix are believed to have been exhausted, but supplies of Hepatyrix are expected to last until the end of the year.
Updated 1 March 2013
Hepatyrix doses released
A consignment of 300,000 doses of Hepatyrix has been made available for use in the UK. It is anticipated that this stock will sell out during May 2013. No further doses are subsequently expected to be made available until the last quarter of 2014.